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Recurrence of focal segmental glomerulosclerosis (FSGS) after renal transplantation impacts long-term graft survival and limits
access to transplantation. We hypothesized that HLA donor/recipient matching could be used as a surrogate marker of recurrence.
In a retrospective study of 42 pediatric and 77 adult subjects with primary FSGS, transplanted from 1990 to 2007 at a single center,
we analyzed the degree of donor/recipient HLA compatibility and other clinical variables associated with FSGS recurrence. There
were total of 131 allografts for primary FSGS (11 subjects were transplanted twice, and 1 had a third allograft) with 20 cases of
FSGS recurrence (17 children) in the primary allograft, and two children who had FSGS recurrence in the second allograft. Fifty-
two subjects (40%) were African American, and 66 (50%) Caucasians. Recurrent FSGS and controls were not diﬀerent for age at
transplant, gender, donor source, acute/chronic rejection episodes, and HLA matches. Recurrent FSGS was not associated with
HLA mismatches; power equals 83%. Immunosuppressive regimen had no eﬀect on recurrence of FSGS, P = .75. Recurrent FSGS
is not associated with HLA mismatching, acute cellular or vascular rejection, and occurs primarily in the pediatric population.
1.Introduction
Primary Focal Segmental Glomerulosclerosis (FSGS) is the
pathologic description of multiple histopathologic variants
[1] of a disease process that results in ﬁbrosis of segments
of multiple renal glomeruli. Recent discovery of genetic
mutationsaﬀectingpodocytestructureandfunctionhaslead
to understanding of a minority of the FSGS pathophysiology
[2–5]. However, the underlying mechanism of the disease
process itself is still largely unknown, and the presence of
a circulating permeability factor has been implicated in its
etiology [6]. In patients with deﬁned podocyte mutations
FSGS only rarely recurs [7, 8] unless associated with that
same permeability factor as shown by Carraro et al. [9].
Primary FSGS without a clear etiology has a high risk
of recurrence of about 30% in the ﬁrst allograft [10].
Furthermore, recurrence rate in the second allograft is even
higher [11]. The episodes of recurrence are managed by
modalities such as plasmapheresis, indicating that humoral
factor is involved in the pathogenesis [12].
The presence of high levels of HLA-speciﬁc antibodies
reduces access to transplantation, increases the risk of
rejection, and impacts long-term graft survival. This is
only partially overcome by improved immunosuppressive
or desensitizing regimens. Whereas risk of acute rejection
in recent years has substantially decreased [13, 14], chronic
rejection remains the most common cause of allograft
failure for which the mechanism is still poorly understood
and may be mediated by a variety of factors including
low levels of immune responses to alloantigens, previous
early episodes of acute rejection, and other variables [15].
HLA donor/recipient mismatching has been associated with2 International Journal of Nephrology
Table 1: Pathologic reports of 22 recurrent Focal Segmental Glomerulosclerosis in renal allograft recipients from 1990 to 2007 at Monteﬁore
Medical Center.
No. LM/IF EM
(1) 8 G: no global or segmental sclerotic/proliferative lesions
IF; 2 G trace IgM mesangial
1Gf o c a lF Pe ﬀacement, focally swollen endothelial cells,
normal GBM
(2)
12 G: 1 globally sclerosed, no segmental sclerotic/proliferative
lesions, scant protein reabsorption droplets
IF; 1 G negative
2Gd i ﬀusely eﬀaced FP, normal GBM
(3)
5 G: tubules with mild atrophy with extensive
dilatation/thyroidization with sparse protein reabsorption
droplets and mild ATN, with absent inﬂammation or ﬁbrosis
IF; 0 G
1 G with mesangial expansion and diﬀusely eﬀaced FP, normal
GBM
(4)
16 G: no segmental sclerotic/proliferative lesions,
focal interstitial chronic inﬂammation
IF; 0 G
3Gf o c a lF Pe ﬀacement, normal GBM
(5)
5 G: no global or segmental sclerotic/proliferative lesions
focal mild interstitial ﬁbrosis
IF; 1 G negative
1Gf o c a lF Pe ﬀacement, normal GBM
(6)
1 G: no global or segmental sclerotic/proliferative lesions
focal mild interstitial ﬁbrosis
IF; 0 G
1Gf o c a l l ye ﬀaced FP with microvillous change, focal loss of
fenestrations, focal areas of prominence of the lamina rara
interna of GBM
(7)
2 G: no global or segmental sclerotic/proliferative lesions,
tubules 100% intact, no ﬁbrosis
IF: 1 G trace mesangial IgM
1Gw i t hf o c a l l ye ﬀaced FP, normal GBM
(8)
25 G: 2 globally sclerosed, with remaining G exhibiting
mesangial expansion with increased matrix
I F ;1Gw i t h1 +I g M
2 G with mesangial expansion and diﬀusely eﬀaced FP, normal
GBM
(9)
12 G: no global or segmental sclerotic/proliferative lesions,
tubules 100% intact
IF; 2 G weak IgG mesangial staining
2Gw i t hf o c a l l ye ﬀaced FP, normal GBM
(10)
7 G: 1 globally sclerosed, one nodule of mesangial matrix, mild
tubular atrophy with mild interstitial inﬂammation
IF; 1 G 1+ IgM mesangial
1 G with patchy eﬀacement of FP and focal areas of prominence
of the lamina rara interna with mild mesangial expansion and
no electron dense deposits
(11)
20 G: majority of normal size and cellularity, but few with mild
mesangial expansion with focal thickening of the glomerular
basement membrane without “spikes” or “splitting”. 1 G with a
central area of hyalinosis
IF; 2 G negative
2Gw i t hf o c a le ﬀacement of FP and mild mesangial expansion,
normal GBM
(12)
29 G: no global or segmental sclerotic/proliferative lesions,
tubules 70% intact with mild atrophy, mild ATN, and mild
interstitial ﬁbrosis
IF; 2 G with 1+ punctuate mesangial deposits and trace IgM
mesangial deposits
1Gw i t hf o c a le ﬀacement of FP and mild mesangial expansion,
no electron dense deposit and normal GBM
(13)
12 G: 1 globally sclerotic G, no segmental sclerotic/proliferative
lesions, tubules 100% intact, no ﬁbrosis,
IF; 2 G with trace + mesangial IgA and + c1q deposits
1 G partial eﬀacement of FP and focally collapsed GBM
(14) 15 G: no global or segmental sclerotic/proliferative lesions
IF; 3 G negative
1 G with focal areas of eﬀacement of FP with microvillous
transformation and normal GBM
(15)
20 G: 2 G with segmental sclerotic lesions with focal epithelial
cell prominence with glomerular capsular adhesions
IF; 5 G with 1+ IgM and trace IgA and c1q
1 G with extensively obliterated FP and normal GBM with
focally ischemic pleating
(16) 6 G: no global or segmental sclerotic/proliferative lesions
IF; 1 G negative 2Gw i t hf o c a le ﬀacement of FP and normal GBMInternational Journal of Nephrology 3
Table 1: Continued.
No. LM/IF EM
(17)
19 G: 1 globally sclerotic glomerulus, no segmental
sclerotic/proliferative lesions, tubules 100% intact, no ﬁbrosis,
IF; 1 G with trace IgM mesangial deposits
1 G with focal areas of eﬀacement of FP with mild mesangial
expansion, no electron dense deposit and normal GBM
(18)
7 G: 1 globally sclerotic G, no segmental sclerotic/proliferative
lesions, focally increased mesangial matrix, tubules 80% intact,
mild tubular atrophy without ATN but with focal protein
reabsorption droplets and mild ﬁbrosis,
IF; 0 G
1 G with scant mesangial electron dense deposits, extensive
eﬀacement of FP, focal swelling of endothelial cells, variably
thickened and pleated GBM with apparent expansion of
mesangial matrix possibly by collapsing capillary basement
membranes
(19)
20 G: 2 globally sclerotic G and 4 segmental lesions with
minimal mesangial cells and matrix increase, minimal tubular
atrophy, ﬁbrosis, and inﬂammation,
I F ;4Gw i t h2 +f o c a lI g M ,t r a c eI g A ,a n d1 +κ and λ light chains
2 G with rare mesangial and subendothelial electron dense
deposits, mild thickening of GBM and intact FP
(20)
7 G: with no segmental sclerotic/proliferative lesions, mildly
increased mesangial matrix, tubules 90% intact, with mild
ﬁbrosis with focal protein reabsorption droplets
I F ;2Gw i t ht r a c eI g M
1 G with focal areas of eﬀacement of FP with mild mesangial
expansion, no electron dense deposit and normal GBM
(21)
16 G: 2 segmental sclerotic lesions, patchy mild inﬂammation
predominantly mononuclear
IF; 6 G, 1+ mesangial IgM and focal trace c1q
1 G with focally obliterated FP and normal GBM
(22)
10 G: no segmental sclerotic/proliferative lesions, tubules 80%
intact with mild focal atrophy and dilatation with scant protein
reabsorption droplets,
I F ;2Gw i t ht r a c ec 1 q
1 G with partially eﬀaced FP, GBM with focal subendothelial
lucencies and focally present inﬂammatory cells in capillary
lumens
LM: light microscopy; IF: immunoﬂuorescence for IgG, IgM, IgA, c3, c1q, κ and λ light chains, Fibrinogen; EM: electron microscopy; G: glomeruli; GBM:
glomerularbasementmembrane;IgA:immunoglobulinA;IgM:immunoglobulinM;IgG:immunoglobulinG;FP:footprocessesofglomerularepithelialcells.
increased incidence of humoral rejection brought about by
production of donor speciﬁc antibodies to HLA antigens
[15,16].Inaddition,increasedHLA-DR4frequencyhasbeen
reported in adult patients with idiopathic FSGS [17], and the
donorHLA-B8maybeassociatedwithriskofrecurrentFSGS
[18].
Considering that there are documented associations (i)
between primary FSGS and increased HLA-DR4 frequency
[17],(ii)betweenrecurrentFSGSanddonorHLAhaplotypes
[18], (iii) between recurrent FSGS and acute humoral
rejection episodes post transplant [19], and the implication
of a humoral factor in the etiology of FSGS and acute rejec-
tion episodes, we hypothesized that HLA donor/recipient
mismatching may be used as a surrogate marker to predict
the risk of recurrence of FSGS in renal allograft patients. No
such analysis has been attempted before to identify unique
markers of recurrent FSGS, as evidenced by nephrotic range
proteinuria or by renal biopsy, in both children and adults.
2.MaterialsandMethods
2.1. Data Collection. We conducted a retrospective review of
the medical records of 119 transplant patients, 42 pediatric
and 77 adult, with the primary diagnosis of FSGS, who
receivedatotalof131transplants(49inthepediatricpopula-
tion, aged 8–21, and 82 in the adults, between the ages of 22
and 80) at the transplant service of the Monteﬁore Medical
Center in the Bronx, NY, from February 1990 to July 2007.
This study was approved by the Institutional Review Board
oftheMonteﬁoreMedicalCenter.Demographicinformation
such as the patients’ date of birth and date and age at trans-
plantation, race, gender, and presence or absence of current
hypertension was obtained from patient medical records.
TissuetypingdatasuchasHLAtypingdataoftheHLAA,
B, and DR subtypes for each patient and donor was available
for all but two patients. Finally, data indicating the use of
pre- and posttransplant plasmapheresis was obtained from
patient medical records.
2.2. Treatments and Deﬁnitions. Diagnosis of primary FSGS
was based on renal biopsy report review by the study
investigators.
Diagnosis of FSGS recurrence in our patient population
was deﬁned as the presence of both nephrotic range protein-
uria of >40 milligrams per m2 per day or urinary protein
to creatinine ratio (UP/Cr) greater than 3.5 and the report of
histological evidence of FSGS on allograft biopsy.
In our center, patients with recurrent FSGS undergo
posttransplant plasmapheresis also known as Therapeutic
Plasma Exchange (TPE). In addition, patients with high pre-
transplant plasma reactive antibodies (PRAs) levels undergo
prophylactic plasmapheresis prior to transplantation to
reduce the likelihood of immediate antibody-mediated allo-
graft rejection.4 International Journal of Nephrology
Table 2: Demographics of recurrent Focal Segmental Glomerulosclerosis in renal allograft recipients from 1990 to 2007 at Monteﬁore
Medical Center.
Data of all transplant recipients
All transplants for
primary FSGS (n = 131)
FSGS recurrence
(n = 22)
No recurrence
(n = 109) P value
Age at transplantation
(years) 29.28 ± 1.26 18.64 ± 2.86 31.43 ± 1.31 <.001
Male 71 (54%) 11 (50%) 60 (55%) .82
Malec 49 (37%) 7 (32%) 42 (39%) .59
African American 52 (40%) 11 (50%) 41 (38%)
.32 White 66 (50%) 8 (37%) 58 (53%)
Other 13 (10%) 3 (14%) 10 (9%)
African Americanc 31 (24%) 6 (27%) 25 (23%)
.65 Whitec 51 (39%) 7 (32%) 44 (40%)
Otherc 10 (8%) 2 (9%) 8 (7%)
Live Donor 50 (38%) 10 (45%) 40 (27%) .63
Cadaveric Donor 78 (60%) 12 (55%) 66 (61%)
Prednisone 117 (89%) 18 (82%) 99 (91%)
.75 Calcineurin Inhibitors 103 (79%) 16 (73%) 87 (80%)
Purine inhibitors 28 (21%) 6 (27%) 22 (20%)
Rapamycin 30 (23%) 4 (18%) 26 (24%)
Data for subgroup of pediatric patients
All transplantsfor
primary FSGS (n = 49)
FSGS recurrence
(n = 19)
No recurrence
(n = 30) P value
Age at transplantation
(years) 15.08 ± 0.62 13.79 ± 1.02 15.9 ± 0.76 .085
Male 27 (55%) 9 (47%) 18 (60%) .56
Malec 15 (31%) 6 (32%) 9 (30%) .71
African American 23 (47%) 10 (53%) 13 (43%)
.80 White 17 (35%) 6 (32%) 11 (37%)
Other 9 (18%) 3 (16%) 6 (20%)
African Americanc 11 (22%) 6 (32%) 5 (17%)
.63 Whitec 10 (20%) 5 (26%) 5 (17%)
Otherc 7 (14%) 2 (11%) 5 (17%)
Live Donor 21 (43%) 8 (42%) 13 (43%) .99
Cadaveric Donor 28 (57%) 11 (58%) 17 (57%)
Prednisone 38 (78%) 16 (84%) 22 (73%)
.061 Calcineurin Inhibitors 35 (71%) 13 (68%) 22 (73%)
Purine inhibitors 16 (33%) 6 (32%) 10 (33%)
Rapamycin 8 (16%) 3 (16%) 5 (17%)
cnumber of subjects, corrected to exclude acute rejection.International Journal of Nephrology 5
Table 3: Recurrent Focal Segmental Glomerulosclerosis in renal allograft recipients from 1990 to 2007 at Monteﬁore Medical Center.
Data of all transplant recipients
All transplants for
primary FSGS (n = 131)
FSGS recurrence
(n = 22)
No recurrence
(n = 109) P value
HLA, mean 1.83 ± 0.14 1.85 ± 0.16 1.73 ± 0.33 .83
HLAc 1.89 ± 0.17 1.91 ± 0.19 1.80 ± 0.45 .81
Number of HLA matches
0 37 (28%) 30 (28%) 7 (32%)
.99
1 23 (18%) 20 (18%) 3 (14%)
2 27 (21%) 22 (20%) 5 (23%)
3 21 (16%) 17 (16%) 4 (18%)
4 13 (10%) 11 (10%) 2 (9%)
5 4 (3%) 3 (3%) 1 (5%)
6 4 (3%) 4 (4%) 0 (0%)
HLA < 3 42 (32%) 27 (25%) 15 (68%)
.99
HLA ≥ 3 10 (8%) 6 (6%) 4 (18%)
PRAm 26.83 ± 3.04 30.19 ± 3.65 14.89 ± 3.76 .036
PRA < 30 32 (24%) 20 (18%) 12 (55%)
.72
PRA ≥ 30 11 (84%) 8 (7%) 3 (14%)
PRAc 23.76 ± 3.67 26.73 ± 4.52 14.38 ± 4.79 .15
PRAc < 30 22 (17%) 13 (16%) 9 (41%)
.99
PRAc ≥ 30 4 (3%) 2 (2%) 2 (9%)
PreTx pp 8 (6%) 5 (5%) 3 (14%) .13
PostTx pp 25 (19%) 8 (7%) 17 (77%) <.001
Acute Rejection 39 (30%) 32 (29%) 7 (32%) .80
Humoral 6 (5%) 6 (6%) 0 (0%)
.29
Cellular 22 (17%) 15 (14%) 7 (32%)
Chronic Rejection 46 (35%) 35 (32%) 11 (50%) .14
Hypertension 63 (48%) 49 (45%) 14 (64%) .16
Data for subgroup of pediatric patients
All transplants for
primary FSGS (n = 49)
FSGS recurrence
(n = 19)
No recurrence
(n = 30) P value
HLA, mean 1.43 ± 0.19 1.42 ± 0.32 1.43 ± 0.23 .92
HLAc 1.39 ± 0.24 1.46 ± 0.43 1.33 ± 0.27 .98
Number of HLA matches
0 16 (33%) 7 (37%) 9 (30%)
.95
1 10 (20%) 3 (16%) 7 (23%)
2 14 (29%) 5 (26%) 9 (30%)
3 4 (8%) 2 (11%) 2 (7%)
4 5 (10%) 2 (11%) 3 (10%)
5 0 (0%) 0 (0%) 0 (0%)
6 0 (0%) 0 (0%) 0 (0%)
HLA < 3 40 (82%) 15 (79%) 25 (83%)
.72
HLA ≥ 3 9 (18%) 4 (21%) 5 (17%)
PRAm 16.68 ± 3.52 13.56 ± 4.12 18.68 ± 5.17 .88
PRA < 30 30 (61%) 12 (63%) 18 (60%)
.72
PRA ≥ 30 10 (20%) 3 (16%) 7 (23%)
PRAc 10.24 ± 3.27 12.63 ± 5.46 8.57 ± 4.08 .526 International Journal of Nephrology
Table 3: Continued.
Data of all transplant recipients
PRAc < 30 21 (43%) 9 (47%) 12 (40%)
.99
PRAc ≥ 30 4 (8%) 2 (11%) 2 (7%)
PreTx pp 8 (16%) 3 (16%) 5 (17%) .99
PostTx pp 20 (41%) 16 (84%) 14 (47%) <.001
Acute Rejection 21 (43%) 6 (32%) 15 (50%) .26
Humoral 3 (6%) 0 (0%) 3 (10%)
.52
Cellular 18 (37%) 6 (32%) 12 (40%)
Chronic Rejection 19 (39%) 9 (47%) 10 (33%) .38
Hypertension 28 (57%) 12 (63%) 16 (53%) .77
cnumber of subjects, corrected to exclude acute rejection.
PRAm: Peak PRA; mean: all subjects.
PRAc: Peak PRA; mean: corrected for absence of any acute rejection (confounder eﬀect).
PreTx pp: Pretransplant plasmapheresis.
PostTx pp: Posttransplant plasmapheresis.
We analyzed our data using STATA (Stata Corporation,
College Station, TX, USA) and Microsoft Oﬃce Excel
(Microsoft Corporation, Redmond, WA, USA). Variables of
interest included number of HLA matches, age at trans-
plantation, time to recurrence, and PRA levels recorded as
absolute values. Variables that were coded as binaries include
the presence or absence of treatment with plasmapheresis,
occurrence or absence of recurrent disease, donor allograft
type (deceased versus live), and race (white, black, Hispanic
or other).
Statistical analysis was performed using Fischer’s exact
test for categorical data and the Mann-Whitney test for
nonparametric variables with a P-value of <.05 being
statistically signiﬁcant.
3. Results
3.1. Demographics of Recurrent Disease. We analyzed 119
patients (42 children and 77 adults) who received 131
allografts for primary FGSG. Forty-two pediatric patients
underwent 49 transplants and 77 adult patients underwent
82 transplants in the period from February of 1990 to July
of 2007. There were total of 131 allografts for primary FSGS
(11 subjects were transplanted twice, and one had a third
allograft) with 20 cases of FSGS recurrence (17 children)
in the primary allograft, and two children who had FSGS
recurrence in the second allograft. All cases of recurrent
FSGS (n = 22) in the allograft had a pathologic report of this
diagnosis (Table 1). Recurrenceof FSGSpost transplantation
occurred in 63.6% of cases within one month: less than 14
days in 7 out of 22 recurrences (31.8%), between 15 and 30
days in another 7 (31.8%), and 36.4% recurrences occurred
beyond31daysposttransplant.Ofthe77adultpatients,only
3 developed recurrences in the allograft, all of them being
in the primary graft. All patients with FSGS recurrence in
as e c o n da l l o g r a f t( n = 2) were pediatric (13 years and 18
years at the age of last transplantation), and in all cases the
ﬁrst allograft was lost due to histopathologic diagnosis of
recurrent FSGS in addition to nephrotic range proteinuria.
Majority of our transplant patients were Caucasians but
40% were African American, and 10% other races (Hispanic,
Asian, and Middle Eastern). Demographic information is
presented in Table 2. There is a statistically signiﬁcant
association between age at transplantation and recurrence as
explained by the higher rate of recurrence in the pediatric
population. This observation has been noted in a previous
report published by NAPRTCS data [20].
TherewasnosigniﬁcantassociationnotedbetweenFSGS
recurrence and acute rejection, chronic rejection, number
of HLA matches, or pretransplant plasmapheresis (Table 3).
There was an expected association between posttransplant
plasmapheresis and recurrence of FSGS in the allograft that
is explained by the fact that one of the core treatment
modalities to deal with recurrence is TPE.
There were higher levels of PRA that were statistically
signiﬁcantinthecontrolgroupascomparedtorecurrentdis-
ease (Table 3). However, when corrected for acute rejection
which is a confounder because it is independently associated
with elevated PRA levels, this apparent relationship becomes
insigniﬁcant. This lack of signiﬁcant association persists
when the PRA levels are divided into two groups of higher
than or lower than 30 (Table 3). Kaplan-Meier analysis
showed that recurrent FSGS-free survival time was similar
in subjects with PRA < 30 and PRA ≥ 30, P = .47.
In the pediatric subset, 43% of the recipients received
organs from live donors and 57% from deceased donors.
There were 19 cases of recurrence in the pediatric age group,
3 of them being in the second allograft. There was no
increased risk of recurrence associated with ethnicity, male
gender, deceases versus live donor organ transplantation, or
the modality of immunosuppression used (Table 2).
Independently, we found that acute rejection is not
associated with HLA mismatching or TPE and there is
no baseline diﬀerence in hypertension between the twoInternational Journal of Nephrology 7
Table 4: (a) Acute Rejection in renal allograft recipients from 1990 to 2007 at Monteﬁore Medical Center. (b) Subgroup of subjects with
acute rejection adjusted for FSGS recurrence in renal allograft recipients from 1990 to 2007 at Monteﬁore Medical Center.
(a)
Data of adult and pediatric patients combined
All transplants for
primary FSGS (n = 131)
Acute Rejection
(n = 39)
No-rejection
(n = 92) P value
Number of HLA matches
0 37 (28%) 10 (26%) 27 (29%)
.36
1 23 (18%) 12 (31%) 11 (12%)
2 27 (21%) 6 (15%) 21 (23%)
3 21 (16%) 5 (13%) 16 (17%)
4 13 (10%) 4 (10%) 9 (10%)
5 4 (3%) 1 (3%) 3 (3%)
6 4 (3%) 1 (3%) 3 (3%)
HLA < 3 42 (32%) 18 (46%) 24 (26%)
.73
HLA ≥ 3 10 (8%) 5 (13%) 5 (5%)
PRAm 26.83 ± 3.04 32.75 ± 5.28 23.76 ± 3.67 .054
PRAc 30.19 ± 3.65 36.35 ± 6.08 26.73 ± 4.52 .068
PRA < 30 32 (24%) 10 (26%) 22 (24%)
.080 PRA ≥ 30 11 (84%) 7 (38%) 4 (4%)
Hypertension 63 (48%) 15 (38%) 48 (52%) .25
HTNc 38 (29%) 8 (21%) 30 (33%) .032
Data for subgroup of pediatric patients
All transplants for
primary FSGS (n = 49)
Acute Rejection
(n = 21)
No-rejection
(n = 28) P value
Number of HLA matches
0 16 (33%) 6 (29%) 10 (36%)
.59
1 10 (20%) 6 (29%) 4 (14%)
2 14 (29%) 5 (24%) 9 (32%)
3 4 (8%) 1 (5%) 3 (11%)
4 5 (10%) 3 (14%) 2 (7%)
5 0 (0%) 0 (0%) 0 (0%)
6 0 (0%) 0 (0%) 0 (0%)
HLA < 3 40 (81%) 17 (81%) 23 (82%)
.99
HLA ≥ 3 9 (18%) 4 (19%) 5 (18%)
PRAm 16.68 ± 3.52 26.75 ± 6.86 10.24 ± 3.27 .024
PRAc 18.68 ± 5.17 31.55 ± 9.41 8.57 ± 4.08 .026
PRA < 30 30 (61%) 9 (29%) 21 (75%)
.14 PRA ≥ 30 10 (20%) 6 (29%) 5 (18%)
Hypertension 28 (57%) 11 (52%) 17 (61%) .77
HTNc 15 (31%) 5 (24%) 10 (36%) .13
PRAc:P R Ap e a k ,m e a nc o r r e c t e dt oe x c l u d eF S G Sr e c u r r e n c ec a s e s .
HTNc: for cadaveric donors.
(b)
Adult and pediatric patients with acute rejection and recurrence of FSGS
All acute rejection
and no recurrence
(n = 21)
PostTx pp
(n = 5)
No PostTx pp
(n = 16) P Value
Cellular rejection 15 (71%) 2 (40%) 13 (81%)
.12
Humoral rejection 6 (29%) 3 (60%) 3 (19%)8 International Journal of Nephrology
(b) Continued.
Adult and pediatric patients with acute rejection and recurrence of FSGS
Pediatric patients alone
All acute rejection
and no recurrence
(n = 15)
PostTx pp
(n = 3)
No PostTx pp
(n = 12) P Value
Cellular rejection 12 (80%) 2 (67%) 10 (83%)
.52
Humoral rejection 3 (20%) 1 (33%) 2 (17%)
groups (acute rejectors versus controls). There is however an
expected association between hypertension and the presence
of a deceased donor allograft (Table 4).
4. Discussion
In our study we present single-center experience with
recurrent FSGS. Recurrent FSGS has been explained by
the existence of a circulating humoral factor called the
FSGS permeability factor as seen in the report of Sharma
et al. [6]. This has been supported by the eﬀectiveness
of postrecurrence plasmapheresis as treatment of recurrent
FSGS in the allograft. In our study we hypothesized that
HLA donor/recipient mismatching may create immunologic
milieu that may enhance production of this factor, and as
such may be used as a surrogate marker to predict the risk
of recurrence of FSGS in renal allograft patients even before
transplantation is performed.
Our study conﬁrmed that there is a positive associ-
ation between recurrence of FSGS and younger age at
transplantation. The 1997 report of NAPRTCS supports
this ﬁnding as well [20]. This is partially explained by
the fact that pediatric FSGS is more aggressively treated
by transplantation than with years of dialysis that is seen
with adult disease before a transplant is considered. The
hypothesis is that dialysis removes, over time, whatever
humoral circulating permeability factor that is responsible
for recurrent disease.
Our hypothesis of a link between HLA donor/recipient
mismatches, a surrogate marker of increased risk of rejec-
tion, and FSGS recurrence was founded in these proposed
humoral mechanisms of recurrent FSGS [17–19]. The results
we obtained deﬁnitely support the association between PRA
levels and acute rejection with a signiﬁcance level of P<. 05,
a result that is expected. On the same note, we reported
an expected signiﬁcant association between posttransplant
plasmapheresis and recurrence, explained by the fact that
the former is the major treatment modality for the latter.
However, recurrence and pretransplant plasmapheresis do
not show any association.
Wecouldnotdrawdeﬁniteconclusionsaboutassociation
of PRA levels in our subjects with recurrence, as PRA testing
has changed from traditional to Luminex-based during the
study observation period. The limitations of this study
include a study population that is skewed towards African
Americans, a group that has traditionally been described
as low risk for recurrence and the limitations of a single
center experience. Another limitation of our study is that
we relied for study entry criteria (primary FSGS) on the
histopathology report from multiple clinical pathologists
(patients were referred to/from outside institutions). Recur-
rent FSGS was deﬁned based on pathology report, rather
than review of individual slides/EM microphotographs, by
the study pathologist. The biopsy reports were not utilizing
Columbia FSGS classiﬁcation, as it was published in 2004.
However, we excluded patients with no glomeruli on the
biopsy report, with no diagnosis of recurrent FSGS, or with
missing biopsy reports.
Although our study did not conﬁrm original hypothesis,
we could state, with a power of 83%, that HLA mismatching
is not a good surrogate marker for predicting FSGS
recurrence. HLA mismatching also did not prove to be
associated with an increased risk of acute rejection, and this
observation is explained by the availability of more eﬀective
modalities of immunosuppression to treat acute rejection,
despite fewer matches. A larger, multicenter study will be
better able to distinguish between the incidence of pediatric
and adult FSGS and the recurrence patterns for each and
study them separately.
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